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Abstract
Background: The objective of this study is to report the costs of Chagas disease in Colombia, in terms of vector disease
control programmes and the costs of providing care to chronic Chagas disease patients with cardiomyopathy.
Methods: Data were collected from Colombia in 2004. A retrospective review of costs for vector control programmes carried
out in rural areas included 3,084 houses surveyed for infestation with triatomine bugs and 3,305 houses sprayed with
insecticide. A total of 63 patient records from 3 different hospitals were selected for a retrospective review of resource use.
Consensus methodology with local experts was used to estimate care seeking behaviour and to complement observed data
on utilisation.
Findings: The mean cost per house per entomological survey was $4.4 (in US$ of 2004), whereas the mean cost of spraying
a house with insecticide was $27. The main cost driver of spraying was the price of the insecticide, which varied greatly.
Treatment of a chronic Chagas disease patient costs between $46.4 and $7,981 per year in Colombia, depending on severity
and the level of care used. Combining cost and utilisation estimates the expected cost of treatment per patient-year is
$1,028, whereas lifetime costs averaged $11,619 per patient. Chronic Chagas disease patients have limited access to
healthcare, with an estimated 22% of patients never seeking care.
Conclusion: Chagas disease is a preventable condition that affects mostly poor populations living in rural areas. The mean
costs of surveying houses for infestation and spraying infested houses were low in comparison to other studies and in line
with treatment costs. Care seeking behaviour and the type of insurance affiliation seem to play a role in the facilities and
type of care that patients use, thus raising concerns about equitable access to care. Preventing Chagas disease in Colombia
would be cost-effective and could contribute to prevent inequalities in health and healthcare.
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Introduction
Chagas disease (American trypanosomiasis) has its origin in the
American continent; however, due to increasing population
migration to North America and Europe, the disease has
expanded beyond its original borders. This parasitic disease has
two principal routes of transmission to humans; by blood-sucking
triatomine bug vectors and by blood transfusion. In 2004 it was
estimated that 3 million Colombians (about 7% of the country’s
population) were at significant risk of infection as they lived in
high-risk areas, and that 1.3 million were infected [1]. The main
health impact of infection with Trypanosoma cruzi (Chagas) is
chronic Chagas disease, which manifests in an estimated 10 to
30% of all infected patients [2]. This happens approximately 15 to
25 years after infection and consists of cardiomyopathies with or
without congestive heart failure. For some patients the disease is
fatal, while for others, expensive medical procedures such as
implantation of pacemakers are needed.
The main prevention strategy to control Chagas infection is to
reduce the triatomine vector population in areas of high
endemicity, using insecticide residual spraying (IRS). Due to
limited resources vector control programmes often target vector
control by spraying (a) all houses in villages that are considered to
be at highest risk, and (b) where risk is low, spraying only those
houses with detectable bug infestations. Hence vector control
programmes need to search for house infestation prior to IRS. The
www.plosntds.org 1 November 2008 | Volume 2 | Issue 11 | e336
effectiveness and cost-effectiveness of IRS to control Chagas
disease has been demonstrated by the Southern Cone Initiative [3]
and in field trials [4–14]. These trials have also shown how results
vary with, for example, choice of insecticide, dose and formula-
tion, spraying strategy (proportion of houses sprayed, and degree
of targeting), spraying methodology, timing and monitoring
systems.
In Colombia, the departments with the highest infestation
prevalences (percentage of houses with triatomines) are Arauca
(21.1%), Casanare (10%), Santander (6.3%), Norte de Santander
(5.2%), Boyaca´ (3.7%), Cundinamarca (1.9%) and Meta (1.7%) [3].
Vector control activities for Chagas disease in Colombia began in
1996 with a pilot vector control programme implemented in the
Departments of Cundinamarca and Santander [15]. Prevention
activities are not yet comprehensive or systematic, with both
sampling and spraying activities varying significantly between the 32
Departments. This variation is partly due to competing priorities for
limited funds, and uncertainty concerning which prevention
strategies are most appropriate. Some Departments have imple-
mented a strategy according to which all houses in the village are
sprayed if house searches in a village detect a prevalence of $10%;
otherwise only positive houses and those located within a 100 metre
radius of the infested house are sprayed.
To date there have been no cost studies in Colombia to shed light
on the resources needed to carry out systematic control activities.
Likewise, there are no estimations of the costs borne by the health
sector for treating Chagas disease patients. The few published
studies available focus only on tertiary and specialised cardiology
hospitals [16,17]. Studies tend to ignore the level of utilisation of
health care, assuming that all patients receive care and that this care
is of a standard level [18,19]. In reality, patients with chronic
Chagas disease live mainly in rural areas, where access and quality
of care is of a different quality compared to urban areas. Patients
requiring specialised care may have to travel or move to urban areas
(with their families), with potentially catastrophic effect on
household income, or may simply fail to access such care.
This study provides the first estimates of the costs and utilisation
patterns of Chagas patients in Colombia in three different levels of
care. A gross estimate of the current burden of Chagas disease and
the main input parameters required to explore cost-effectiveness
analysis of Chagas disease prevention are also provided.
Methods
Costing vector control activities
Three departments (Norte de Santander, Santander and
Boyaca´) from the most endemic regions of Colombia participated
in the study. In a retrospective analysis, a total of 6389 houses that
registered vector control activities in the last 6 months was
included, 3084 houses for entomological survey and 3305 for
spraying. The specific municipalities and villages that compose the
sample (see Table 1) had been prioritised for vector control
activities by the Chagas control programme managers the previous
year. All localities in which interventions were made were in rural
areas; however, the dispersion of houses varied across localities.
We did not conduct household surveys to carry out this analysis;
records on resources used in these activities were provided by the
staff in charge of vector control programmes, who were also
interviewed about the operational aspects of these activities.
Entomological surveys
In all sites the entomological surveys consisted of timed manual
collections (one –person-hour per house), combined with the
distribution of pots to householders to collect triatomines after the
search. The entomological surveys also included geographical
reconnaissance (for mapping in Geographical Information Systems),
epidemiological stratification and the implementation of Triatomine
Information Posts (TIP) in the villages. In these posts, usually based in
public schools, neighbors can obtain information and report
triatomines found in houses. TIPs constitute the basis of post-
spraying surveillance.
The surveys were conducted by trained assistants and
technicians in team sizes that varied depending on the area of
intervention. For example, in the field sites in Boyaca, teams
consisted of 3–6 people, and averaged 10 houses surveyed per
person-day. In Santander and Norte de Santander, with more
remote rural areas, dispersed houses, and poor or absent roads, the
rate of surveying was about half this value.
Spraying activities
In Santander and Norte de Santander spraying teams
comprised one technician or supervisor and 3 or 4 assistants. In
Boyaca´ spraying teams comprised 5 assistants and a driver.
Technicians in Boyaca´ participated only in the organisational
aspects of spraying, which included conducting a sensitisation
campaign using Information Education and Communication
(IEC) strategies, and training assistants in spraying techniques.
These also engaged key community stakeholders, delivered leaflets
and organised community workshops in the villages. In these
workshops, households were taught to reorganise their house
contents and their peridomicile so as to reduce the risk of
triatomine reinfestation after spraying.
Deltamethrin (K-Othrine SC 50 Bayer) was the main insecticide
used in all sites; however, in Norte de Santander Lambdacyhalo-
thrin (Icon 10 PM) was also used to spray some houses. A litre of
insecticide was used to spray approximately 10 houses. Follow-up
and quality control of spraying were carried out by supervisors in
10% of the houses intervened in Boyaca´. This was not done in
Santander or Norte de Santander.
Salary rates of field workers (i.e. full cost of employment per
month in US$ of 2004) were slightly higher in Norte de Santander
and Santander, where a technician and an assistant earned $616
and $541, respectively. These were lower in Boyaca´ where a
Author Summary
Chagas disease is one of the most important vector-
transmitted diseases in Latin America. Many patients with
Chagas go undiagnosed for years, and because symptoms
of the chronic condition are similar to those of other
cardiac conditions, the burden of the disease is not
evident. This leads to underestimation of the burden that
Chagas disease places on healthcare resources, which in
many cases translates into inadequate prioritisation for
prevention. This study assessed the cost of Chagas disease
in Colombia in comparison to the cost of prevention.
Measuring the cost of treatment for Chagas disease is
challenging. In this study we used a method that combines
retrospective review of costs for prevention activities and
for treatment of chronic Chagas disease patients, and we
estimated utilisation of services using experts’ consensus.
We found that the cost of treating Chagas disease is
substantial, even though many people are not receiving
appropriate care. On the other hand, we show that
preventing Chagas disease transmission through insecti-
cide spraying activities is affordable in Colombia and
therefore should be conducted more systematically. This
study provides the basic inputs to conduct a full economic
evaluation of Chagas disease prevention.
Costs of Chagas Disease in Colombia
www.plosntds.org 2 November 2008 | Volume 2 | Issue 11 | e336
technician earned $546 and an assistant $418. However, in
Boyaca´ salaries of supervisors were around $1,180 per month
(compared to $760 in Norte de Santander). Per diems were higher
in Santander, with a range from $15 to $25 per person-day, and
lower in Boyaca´ with rates between $10 and $15 per person-day.
Costing methodology for vector control
From a healthcare provider perspective, the cost per house
entomologically surveyed and the cost per house sprayed were
determined using standard costing methodology [20,21] We
combined an ingredients approach (i.e. aggregating one by one the
resources involved in each activity) with step-down method (i.e.
identifying total monthly/annual expenditures per category and
disaggregating them for our activities/time of interest) [21]. We
differentiated between direct and indirect (or overhead) costs. All
cost data were adjusted for inflation to 2004 prices and converted
to 2004 US dollars. The exchange rate observed in December
2004 was 2,430 Colombian pesos (COP) to one US$, as reported
at www.oanda.com. Direct costs included field workers (their
salaries and per-diems), supplies (consumables used for entomo-
logical surveys and for spraying) and transport (use of vehicles, fuel
and maintenance costs). Straight line depreciation was used to
reflect the cost for the use of capital items, mainly vehicles (10
years lifespan) and Hudson X-pert type hand-compression
sprayers (5 years). Indirect costs (or overheads) in all sites included
professionals time (their salaries and per-diems) and transport costs
associated with planning and supervision of control activities.
These covered personnel from the department and municipalities.
In the case of Boyaca´, direct costs also included the sensitisation
campaigns, IEC strategies, and the community workshops, as
these activities were carried out systematically in all villages before
spraying. These costs were based on salary rates, per-diems and
transport of the personnel from the municipality that carried out
these activities. For simplicity, we did not include as indirect costs
the time of community stakeholders and households that
participated in these activities. Thesewere not paid for their
participation on these activities
Costing treatment of chronic Chagas disease
Treatment costs were evaluated from a payer perspective (i.e.
patient-insurance-government) in line with new (insurance-based)
financing system. We differentiated between 3 levels of care: basic
(primary care where Chagas disease is not diagnosed and
suspected cardiomyopathy patients are referred on); intermediate
(district and regional hospitals where diagnosis is possible along
with non-surgical or palliative and preventive care for cardiomy-
opathy), and specialised (metropolitan hospitals that can carry out
complex procedures such as pacemaker implantation).
A total of 63 patients’ records was included in the analysis. Of
these, 31 were identified in the municipal hospitals of Soata´ and
Moniquira´ (Department of Boyaca´), where vector control activities
were evaluated. Each of these hospitals serves a population of
around 20,000 inhabitants. The other 32 patients were selected in
the specialised cardiovascular hospital in Bogota´, Fundacio´n Clı´nica
Shaio. The protocol or consultation of patients’ records was
approved by the committee of ethics and research of the Fundacio´n
Clı´nica Shaio. Based on this approval, the directors of the three
institutions gave permission for consultation of patients’ records.
These institutions were selected to represent a relevant mix of care,
with Boyaca´ hospitals (located in semi-rural settings) classified as
providing an intermediate level of care, while the Fundacio´n Clı´nica
Shaio provides specialised cardiovascular care. Previous links on
Table 1. Unit costs per house surveyed and sprayed (US$, 2004).
Cost item/ Department
(Municipality)
Norte de Santander
(Cucuta´)
Santander (Macaravita,
Capitanejo) Boyaca´ (Soata´)
Boyaca´
(Moniquira´)
Total weighted
average
Cost per house surveyed
Number of houses 43 285 795 1961 3084
Cost categories
Staff salaries 216.8 46% 732.1 33% 1664.0 54% 4181.1 54% 6794.0 50%
Per diems 164.9 35% 759.0 34% 1038.6 33% 2614.0 34% 4576.6 34%
Supplies 14.1 3% 87.9 4% 163.7 5% 402.9 5% 668.6 5%
Transport - 560.8 25% 163.1 5% 392.5 5% 1116.4 8%
Indirect costs/ overheads 75.4 16% 69.0 3% 71.2 2% 135.8 2% 351.4 3%
Total Costs 471.3 100% 2208.8 100% 3100.5 100% 7726.3 100% 13,506.9 100%
Unit cost per house 11.0 7.8 3.9 3.9 4.4
Cost per house sprayed
Number of houses 61 661 761 1822 3305
Cost categories
Staff salaries 397.2 15% 2927.7 27% 4527.7 20% 10 656.5 20% 18,509.18 21%
Per diems 294.8 11% 3035.5 28% 2776.8 12% 6548.1 12% 12,655.25 14%
Insecticide (Deltamethrin) 1740.9 67% 2343.7 22% 13 759.7 61% 33 133.0 62% 50,977.32 57%
Transport 79.0 3% 560.7 5% 441.7 2% 1014.2 2% 2,095.54 2%
Other direct supplies 48.9 2% 376.2 4% 186.7 1% 438.0 1% 1,049.78 1%
Indirect costs/ Overheads 23.8 1% 1497.4 14% 787.4 4% 1740.5 3% 4,049.04 5%
Total Costs 2,584.6 100% 10,741.3 100% 22,479.9 100% 53,530.4 100% 89,336.1 100%
Unit cost per house 42.4 16.3 29.5 29.4 27.0
doi:10.1371/journal.pntd.0000336.t001
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Chagas disease research facilitated access to these institutions. We
did not include primary healthcare centers in the sampling as
patients with symptoms of cardiomyiopathy are referred on,
normally without Chagas disease diagnosis. However, we still
estimated cost associated with this level of care (see next section).
Data collection and data analysis on treatment costs
In the three hospitals, records of all patients registering visits due
to heart disease between January 2000 and August 2004 were
reviewed. Patients were included in the study if (1) Trypanosoma
cruzi infection was confirmed, and (2) the presence of Chagas
cardiomyopathy symptoms was the reason for seeking care. At the
basic level of care, costs of treatment were drawn from the
estimations on utilisation carried out by the expert panel and the
unit costs of consultations. The former, included the frequency of
visits to a General Practitioner (GP) and the probability of
hospitalisation per year.
For each hospital a database was created in Excel to register and
analyse chronologically all services that each patient had received
since the first chronic Chagas-related visit. The duration of
treatment varies from patient to patient; while some patients have
completed one year, others have been on treatment for up to ten
years. The services consumed by the patients were grouped into
ambulatory care, visits to emergency services, in-patient bed-days,
clinical and other diagnostic investigations or procedures, surgical
procedures, and other medical procedures (e.g. rehabilitation if
applicable). Total costs were obtained by multiplying unit costs
(based on hospital charges updated to 2004 values) by the quantity
of services consumed. For valid interpretation, results are
expressed as the weighted mean cost per patient per year for
each level of care.
In each level of care, costs were analysed separately for patients
with Cardiomyopathy (C) with congestive heart failure (CHF) and
patients with C without CHF. Given the relatively small sample
size and the focus of the study on economic burden, we did not
seek to associate specific levels of disease progression with costs.
However, for the specialised level of care, a detailed account of the
interventions and procedures received by patients is provided in
the results section.
Care-seeking behaviour and utilisation patterns
Consensus development techniques, such as Delphi methods,
use expert panels to gather information for which there is not
strong evidence. These have been used in a variety of contexts
[22,23] including economic evaluations [24]. As the proportion of
patients that access each level of care had not previously been
measured, nor was it known how soon patients seek care after
onset of first symptoms of cardiomyopathy, a panel of experts from
Colombia was assembled. The panel included medical doctors
(GPs, cardiologists), Chagas vector control managers and other
professionals related to health care arrangements in general and
Chagas disease in particular. All participants were sent instructions
with a set of 9 forms for completion in advance of the panel
meeting. These aim to specify healthcare facilities that were likely
to provide services to Chagas chronic patients and to identify
pathways of care. Specifically, participants were asked: (1) to
classify these facilities to one of the three levels of care; (2) to
describe the referral system between the three levels of care with
focus on the empirical rather than the written norms; (3) to
estimate healthcare seeking behaviour at first symptoms of Chagas
chronic disease (what proportion seek care and where); and (4) to
estimate dynamics of the pathway of patients through the
healthcare network after first symptoms.
The Delphi exercise was conducted in 3 steps; input, discussion
and review (iterative in each round) and conclusions:
a) Input: All available and recent data (from local sources) on
various determinants of utilisation in Chagas disease were
reviewed, such as epidemiology, demographic and healthcare
structure. Healthcare insurance coverage rates (urban/rural),
care-seeking and utilisation patterns were reviewed from the
results of a national household survey [25]. Further
information on the current situation of treatment of chronic
Chagas disease in line with the new financing system was
reported by representatives of the central level [26].
b) Discussion and review: Participants were separated into
three groups, each with a range of specialization and
geographical origin of participants. In the first round of
consensus, participants were instructed to generate new
‘‘reviewed’’ individual estimates (after presentation of all
available evidence). A second round included discussion
among participants of each group, after which consensus was
reached to produce only one set of estimates per group.
c) Conclusion: Finally the three groups presented their
consensus results, followed by, discussion, especially about
parameter estimates that varied widely across groups. After this
final discussion, groups had a chance to change any estimated
parameter values. The final output of the Delphi was estimated
by averaging results from the three groups. The parameter
estimates generated through this process included:
a. The proportion of patients that do not seek care (apart from
palliative care near death).
b. The proportions that seek care at each level.
c. The average number of years that patients are treated in each
level of care.
d. The proportion of patients with C, with and without CHF,
that seeks each of the three levels of care.
Using the information on unit treatment costs and the
parameters on utilisation derived from the consensus exercise,
we estimated the expected lifetime costs of treatment for a patient
with chronic Chagas disease in Colombia. We used a 3% discount
rate on future costs to reflect the current long-term opportunity
cost of capital in Colombia.
Results
Vector control activities
Total and average costs are presented in Table 1. The average
weighted cost per house surveyed was found to be $4.4, while the
average cost per house sprayed was $27. For surveying, on
average, salaries accounted for 50% of the total cost, followed by
per-diems (34%) and transport (8%). However, variation can be
observed across sites, especially with respect to salaries, transport
and indirect costs. The highest mean cost is registered for Norte de
Santander, where the intervention area had no access for vehicles
and the houses were geographically dispersed.
In relation to spraying activities, the cost of the insecticide was
on average 57% of the total cost per house sprayed. However, in
Santander it was only 22%, as the insecticide had been purchased
through the central government at the comparatively low price of
US $33 per litre. In Colombia the central level negotiates the
purchase of high volumes of insecticide for malaria and Chagas
disease programmes, based on the Departments estimation of
needs budgeted in the previous year. When Departments run out
Costs of Chagas Disease in Colombia
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of centrally-purchased insecticide, they have to purchase it directly
from private providers. This was the case of Norte de Santander and
Boyaca´ where US $180 per litre was paid. Such disparities have
been described in a recent paper on the cost of spraying for
malaria control [27]. The next most important resource inputs in
the cost per house sprayed were salaries at 21%, followed by per-
diems at 14%.
Treatment costs at each level of care are summarised in Table 2;
these costs are disaggregated further in the subsequent tables.
Average annual costs of chronic Chagas disease patients with C
with CHF were higher than costs for patients with C without CHF
in all levels of care. The costs of care rise considerably from
primary to tertiary care providers. In the basic level of care annual
treatment for patients with C with CHF consists of 3 GP visits and
0.58 days of hospitalisation, while for patients with C without CHF
this consists of 5.3 GP visits and 0.25 days of hospitalisation.
Treatment results for intermediate level of care
Patients from Soata´ Hospital have a mean age of 68.3 years
(range 49–85). More than half of them (56%) were from Soata´
municipality while the rest were from neighbouring municipalities,
and 63% were males. In Moniquira´ Hospital the age structure was
very similar: mean age 67.2 years (range 49–83). Here only one
patient did not come from Moniquira´ municipality, and 47% were
males. We did not collect data on patients’ addresses and therefore
we cannot state with precision the proportion of patients that lived
in rural areas. However, it is highly likely that most of the patients
seeking care in Soata´ and Moniquira´ hospitals (both located in
semi-rural areas) were infected and possibly still live in rural areas.
All patients selected in Moniquira´ hospital had C with CHF. In
these two hospitals 4 patients had died due to the disease. All
patients sampled in this level of care were insured, with 93.5%
belonging to the subsidised healthcare regime, meaning that these
patients were relatively poor with an income under one legal
minimal salary (#US $ 138 per month). The remaining 6.5% were
in the contributive regime.
Table 3 shows that in the intermediate level of care, patients
with C with CHF experienced at least twice as many hospitalisa-
tion days as patients with C without CHF. However, the latter
group had more GP visits per year. Thus, while hospitalisation is
the larger cost component for patients with C with CHF,
medicines are the larger component for patients with C without
CHF. Patients from the hospital of Moniquira´ had a longer
average time on treatment at the time of research (7.5 years), while
patients form Soata´ hospital have been on treatment for just over 2
years on average.
Treatment cost in the specialised level of care
In the Foundacio´n Clı´nica Shaio 75% of the 32 patients were
females. Patients were generally younger than those from
intermediate care hospitals, with a mean age of 53.4 years (range
34–78); 38% of the patients came from Boyaca´ Department (the
nearest Chagas disease endemic Department), 25% from Santan-
der and 37% from other endemic departments. There were 17
patients classified as C with CHF, 13 classified as C without CHF,
and the type of cardiomyopathy remained unclear in two patients.
One patient had died due to the disease. All patients were insured
through the contributory regime, and therefore were less poor
than those who used intermediate level care.
The services that patients received in the specialised level of care
increased considerably in complexity and costs. Table 4 shows that
the largest component of cost was surgical procedures, reaching 41%
and 55% of total annual costs for C with and without CHF,
respectively. Overall, there were 16 patients that had a pacemaker
implanted (9 with C with CHF and 7 without). Two other patients
had cardiac transplants, one had a cardio-defibrillator implant, and
another had a cardiac re-synchroniser. Medicines and drugs were the
second highest component of cost, reaching 24% and 10% for
patients with C with and without CHF, respectively. The patients had
been under treatment for a relatively short time, on average 1.4 years
(range 1–9). In this level of care, patients with C with CHF received
considerably more services than those without CHF (see Table 4). For
example, the former averaged 20 attendances by specialists per year,
compared to only 8 for patients with C without CHF. On average, a
patient with C with CHF had 12.6 days of general hospitalisation and
1.6 days in an intensive care unit (ICU) per year. This is reduced to 5.8
days of general hospitalisation and 1 day in ICU for patients with C
without CHF. Finally, the number of laboratory investigations was
three times more in patients with C with CHF.
Health seeking behaviour and healthcare utilisation
The consensus of experts was that the majority (54%) of patients
feeling the first symptoms of chronic Chagas disease will seek care
first in the basic level of care, 22% will not seek care, 19% will go
straight to an intermediate level of care (such as the Hospital of
Soata´ or Moniquira´) and only 5% will go immediately to a
specialised level of care (see these values on the left of each arm in
Figure 1). Patients tend to seek care late, when the symptoms
worsen, which occurs on average ten years after clinical onset of
the cardiomyopathy. When patients seek care they follow different
pathways within the health care system depending on various
factor, such as insurance coverage, severity of the condition, place
of residence and patient’s resources. They are eventually treated
Table 2. Annual expected cost of patients in different level of care (US$, 2004).
Mean cost per patient-year Cardiomyopathy with CHF Cardiomyopathy without CHF
Basic level of care
Average cost $51.4 $46.4
Intermediate level of care (ILC)
H. Regional de Soata´ $237.9 (n = 11) $188.0 (n = 5)
H. Regional de Moniquira´ $275.0 (n = 15)
Weighted average (ILC) $259.3 (n = 26) $188.0 (n = 5)
Higher level of care
Fundacion Clı´nica Shaio $7,980.9 (n = 17) $3,651.5 (n = 15)
n = number of patients in the analysis.
doi:10.1371/journal.pntd.0000336.t002
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predominantly in one specific level of care. For simplicity we did
not attempt to model annual transition probabilities across levels
of care, instead we used a decision tree to present the Delphi
consensus estimates (Figure 1). These estimates were used to
ascertain average lifetime utilisation patterns for patients with
chronic Chagas cardiomyopathy in Colombia.
Figure 1 shows all possible routes that a patient can follow when
seeking treatment to be finally treated predominantly in one level
of care. To ascertain the total proportion of patients that are
treated in each level of care, we sum up for each level of care, the
probability estimates appearing in the terminal node of the arms
that end in that specific level of care. Thus, derived from Figure 1,
24% of the patients are treated predominantly in facilities
corresponding to basic level of care, while the majority (42%) is
predominantly treated in intermediate level of care and only 12%
are treated in the specialised level of care. The proportion that
does not seek care, apart from palliative care near death, was
estimated at 22%. For costing purposes, it was assumed that
seeking care near death would cost, on average, the equivalent of
two years of intermediate level care.
Merging information on annual cost of treatment (Table 2) and
utilisation patterns (Figure 1) we estimated an average expected
annual cost per chronic Chagas patient in Colombia of $ 1,028 as
shown in Table 5. This figure accounts for the probability that
patients seek care in different levels of care according to type of
cardiomyopathy and patient characteristics. Lifetime duration of
chronic cardiomyopathy (in years) was also drawn from the expert
panel for the different groups of patients. This allowed the
estimation of the approximate lifetime costs on treatment for a
chronic Chagas disease patient in Colombia. Table 5 shows that,
on average, a chronic patient in Colombia would cost $11,619
(US$, 2004) in treatment during their lifetime.
Discussion
The cost results of this study and those reported by the
international literature are shown in Table 6. The costs of vector
control activities were lower in comparison to previous studies and
these were highly dependant on the cost of the insecticide.
Treatment costs varied widely among different levels of care and
between patients with C with and without CHF. Care seeking
behaviour and utilisation patterns suggest that patients delay
treatment; most of them received care of an intermediate level
(42%); few would use specialised levels of care (12%), and 22%
would remain untreated except for palliative care near death.
The main cost component of the vector control programme is
the cost of spraying houses. Our finding of $27 per house seems
very favorable when compared to previous cost estimations e.g. for
the southern cone [28]. This cost was also lower than the cost of
spraying houses for malaria control in Colombia, where using
mainly Lambdacyhalothrin [Icon 10WP] a high level of insecticide
wastage per house was reported [27]. In this study, insecticide
accounted for 57% of total costs. However, most of the sites had
paid a relatively high price, as purchases have been made
individually from the Department rather than from the Ministry of
Health (MOH). In 2004 the MOH’s national negotiated price was
only $33 per litre for Deltatmethrin (K-Othrine sc 50 Bayer). This
suggests that better planning and coordination would lead to
significant savings in the costs of spraying houses. We estimated
that if the three Departments would have used insecticide bought
at central level prices, the mean cost per house sprayed could have
been reduced from $27 to $16.
Annual treatment costs for chronic Chagas disease patients
varied from $46 for a patient with C without CHF treated in basic
care to around $7,900 for a patient with C with CHF that used the
Table 3. Total cost per patient-year and services consumed in intermediate level of care (US$, 2004).
Mean cost/services per patient-year
H. Soata´ (C with
CHF)
H. Moniquira´ (C
with CHF)
Cost profile (C with
CHF – both hospitals)
H. Soata´ (C
without CHF)
Cost profile (C
without CHF)
Cost categories n= 11 n= 15 n= 5
Outpatient visits 20.4 15.2 7% 33.7 18%
Diagnostic investigations 40.5 26.9 13% 28.6 15%
Medicines 66.4 93.3 31% 78.4 42%
Hospitalisation 110.7 139.6 49% 47.3 25%
Total cost (US$) 237.9 275.0 100% 188.0 100%
Years on treatment 2.6 (1.0–13.8) 7.5 (1.0–22) 2.3(1.0–4.4)
Mean number of health services consumed per year
Outpatient visits
GP visits 2.2 1.6 4.5
Visit to specialist 0.4 0.3 0.4
Emergency admissions 0.5 0.3 0.3
Diagnostic tests
Electrocardiograms 1.1 0.7 1.0
Various laboratory tests 3.5 1.4 2.2
Thorax x-ray 0.6 0.4 0.3
Hospitalisations
Bed-days 2.4 2.6 1.0
Other procedures (oxygen administration,
respiratory therapy, etc)
- 2.3 -
n = number of patients in the analysis.
doi:10.1371/journal.pntd.0000336.t003
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specialised level of care. This 30-fold increase in costs reflects the
different type of care (and potential differences in health outcomes)
offered in these institutions. However, this dichotomous situation
observed between intermediate and specialised care cannot
reliably be generalised countrywide, as it is possible that other
hospitals in Colombia, such as provincial hospitals, offer services
whose complexity and costs lie between these two types of facilities.
Among the international literature reporting Chagas disease
patients’ treatment costs, Schenone [17] reported annual costs
from public hospitals in Chile. These costs lie between our
intermediate care costs and those for specialised levels of care,
suggesting that the care provided in Chile was potentially more
complex than that provided in the municipal hospitals of
Colombia but not as complex as this offered by the Fundacio´n
Clı´nica Shaio. The costs observed in the Fundacio´n Clı´nica Shaio are
in line with a Mexican study from the National Institute of Cardiology
where the cost per patient admitted varied from $4,463 to $11,839
depending on the type of admission [16]. Estimations done in
Brasil [19], reported lifetime costs of an infected patient
(irrespective of developing chronic condition) averaging $3,864,
which as expected, is lower than our estimation of $11,618.57
which considers only chronic patients.
Many of the previous studies have not reported or reflected on
patients’ care-seeking behaviour and utilisation patterns. The
expert panel estimated that 22% of patients do not seek care and
from those who do so, not all of them have access to a specialised
level of care such as a cardiology hospital. In Colombia, the
healthcare financing system is undergoing a major reform that
seeks to improve access to health care by reaching universal
coverage [29]. However, data for the time of the study showed that
only 52% of the population had insurance coverage, and in rural
areas this percentage dropped to 40%. Bitra´n and colleagues have
reported that uninsured patients restrict their demand for
healthcare even when they seem to have more needs [30].
Table 4. Distribution of mean cost by type of service and cardiomyopathy in specialised level of care (US$, 2004).
Mean costs per patient-year C with CHF C without CHF
n = 17 n = 13
Ambulatory care (includes outpatient visits and telemetry) 48.5 1% 42.3 1%
Hospitalisation
Emergency admissions 11.8 0% 3.4 0%
Bed-days general 504.1 6% 190.5 5%
Bed-days in intensive care unit (ICU) 504.2 6% 269.7 7%
Procedures in hospitalisation
Electrocardiography 58.1 0% 21.2 0%
X-rays 80.6 1% 29.8 1%
Laboratory 416.4 5% 72.9 2%
Medicines & drugs 1,887.8 24% 372.1 10%
Surgical procedures & surgical elements 3,261.8 41% 2,018.3 55%
Electrophysiology 319.4 4% 241.3 7%
Rehabilitation, physiotherapy, etc. 543.3 7% 256.9 7%
Other procedures 344.9 4% 133.1 4%
Total annual cost per patient 7,980.9 100% 3,651.5 100%
Mean services per patient-year
Outpatient appointments 1.3 0.6
Hospital procedures
Emergency admissions 0.3 0.2
Attendances by specialist 20.0 8.1
Bed-days general 12.6 5.8
Bed-days intensive care unit 1.6 1.0
Laboratory investigations 68.6 21.4
Thorax x-ray 2.9 1.5
Cardiology diagnostic techniques 1.1 0.9
Electrophysiological assessments 0.4 0.5
Imaging heart study 0.7 0.1
TAC (computed-tomography) 0.1 0.1
Surgical procedures
Pacemaker implantation 0.4 0.4
Cardio-defibrillator implantation 0.02 -
Cardiac re-synchronizer 0.02 -
n = number of patients in the analysis.
doi:10.1371/journal.pntd.0000336.t004
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Figure 1. Health seeking behaviour and pathway of Chagas disease patients through the levels of care. This decision tree shows all
possible routes that a patient can follow to be finally treated predominantly in one level of care. The letter ‘‘p’’ in the box to the right indicates the
probability that a patient follows that specific route of care. For example, the tree arm whose terminal node is next to the arrow corresponds to the
route where the patient seeks care first in a facility that provides basic care, s/he is then referred to a facility that provides intermediate level of care
and will remain there during the course of the treatment. This pathway of care will be followed by 24.8% of the patients (p = 0.248).
doi:10.1371/journal.pntd.0000336.g001
Table 5. Total expected mean cost per patient, weighted by care seeking and utilisation patterns (US$, 2004).
Patient group
Annual
treatment cost
Utilisation rate
by level of care a
CHF & NCHF split
by level a
Disease duration
years a
Estimated lifetime
cost b
Do not seek care CHF 34.9 c 0.22 50% 20 $518.6
Do not seek care NCHF 19.2 c 0.22 50% 30 $376.0
Basic level of care CHF 51.4 0.24 80% 30 $569.0
Basic level of care NCHF 46.4 0.24 20% 40 $676.7
Intermediate level of care CHF 259.3 0.42 85% 30 $2,870.5
Intermediate level of care NCHF 188.0 0.42 15% 40 $2,741.9
Higher level of care CHF 7,980.9 0.12 90% 30 $88,350.5
Higher level of care NCHF 3,651.5 0.12 10% 40 $53,255.6
Mean expected cost per patient $1,028.21 $11,618.57
aAll these estimations were obtained from the consensuses of the expert panel (refers to figure 1).
bLifetime costs were calculated as the present value of annual costs accounting for the disease duration (minus ten-year delay for seeking care) and 3% discount rate.
cPatients who do not seek treatment care, apart from palliative care near death, were assumed to spend an equivalent cost to two years in intermediate level of care
(value also annualised).
doi:10.1371/journal.pntd.0000336.t005
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Although in theory uninsured patients have the right to receive care,
there are concerns as to the extent that this materialises in practice.
The health insurance system implies that different third-party-
payers (or insurers) reimburse health facilities that serve subsidised,
contributive and uninsured patients. It has been reported that the
insurers that cover the uninsured and the subsided patients have faced
financial solvency problems thus delaying reimbursements to
healthcare facilities. Hospitals on the other hand, which have been
made autonomous in this reform and therefore seek to increase
revenues, avoid the admission of patients whose insurers do not keep
payments up-to-date, and in some cases have implemented up-front
out-of-pocket payments of drugs and other procedures for these
patients, which are often poorer than average [26].
We acknowledge the limitations of our study in terms of the
relatively small sample of patients (64), as well as the potential
limitations of the Delphi exercise at ascertaining care seeking and
utilisation patterns. Nonetheless, we believe that this information
can help to guide policy decisions on prevention of Chagas disease.
Vector control managers in Colombia (as well as in other countries)
can use these costs and methods as a reference when planning future
control activities. As the insecticide is the main cost driver of
spraying, they need to plan in advance, and aim to purchase most or
all insecticides at the lower prices that can be achieved from the
central level. We found that different sites use different operational
arrangements when carrying out vector control activities. Vector
control managers need to use resources wisely, engaging in multi-
sectorial approaches and involving community stakeholders, as
these can play an important role on activities such as surveillance.
Education and community participation can have an important
impact on the sustainability of vector control, both for Chagas
disease and other infectious diseases. The impact of community
participation in the sustainability of vector control activities for
Chagas disease has been recently demonstrated by Gu¨rtler and
colleagues [31] in the Gran Chaco, Argentina.
An area that deserves further research is the degree of
(equitable) access to a standard level of care for chronic Chagas
disease patients in Colombia. In our study, patients who used
intermediate levels of care were poorer compared to those that
used specialised care. In the former group 93% were members of
the subsidised regime (i.e., they are entitled to a much more limited
package of care than those in the contributive regime) while patients
that used specialised care were all members of the contributive regime.
Overall, we did not found uninsured patients demanding care for
Chagas cardiomyopathy, despite the fact that 60% of the
population in rural areas were uninsured in Colombia in the year
2000 [30]. This poses questions as to how the lack of insurance
coverage could deter care seeking, not only in relation to Chagas
disease patients, but even more generally.
The extent to which the costs of vector control activities can be
offset by potential savings on treatment averted is a more complex
analysis that lies outside the scope of this article. Chagas disease
has specific characteristics, because not all patients develop
chronic disease, and for those affected, this happens 15–20 years
after infection. Current control activities will deliver benefits
mainly in the future, as fewer people become infected and develop
the chronic condition. Thus, applying the common practice in
economic evaluation of adjusting costs and health outcomes for
time difference, process known as discounting [21], would have the
impact of reducing the benefits of Chagas prevention in
comparison to control of other diseases, for which benefits would
accrue sooner.
In general, vector-borne transmitted diseases require the use of
modelling to evaluate control activities in conjunction with
infections averted. Thus, an estimation of current burden of
Chagas disease in Colombia is challenging, as it is not known how
many individuals are currently chronic patients and whether their
seeking behaviour is well represented by the estimate done by the
expert panel. However, using estimations of 1.3 million infected
Colombians [1], we can estimate the approximate annual cost of
treatment across the population. If 20% develop chronic
conditions, this would translate into 260 thousand people receiving
care, with annual costs of treatment of $1,028 per person, leading
to an economic burden of around US$ 267 million per year (US$,
2004). This estimation does not include infected patients who have
not developed chronic conditions. The latter needs to be
investigated to ascertain the extent to which these patients are
also a burden on the healthcare system. According to a national
entomological survey, there were 178,519 dwellings considered of
high risk for Chagas disease in Colombia [1], which should be
prioritised for insecticide spraying. Using our results on costs of
prevention, spraying these houses would cost nearly five million
dollars, which is around 2% of expected annual expenditure on
care. Again, these figures need to be treated with caution since
they are not directly comparable, as it may be appropriate to apply
discounting to the future benefits of vector control. Furthermore,
reinfestation, implies that a long term surveillance system to survey
and re-spray reinfested houses, needs to be in place even after
spraying all the houses. These rough estimations nonetheless seem
to suggest that preventing Chagas disease in Colombia may be
cost-effective in comparison to treating disease, with the potential
of accruing not only economic savings, as well as more
importantly, avoiding disability and suffering. A more compre-
hensive analysis on the cost-effectiveness of control activities over
time is addressed in a separate paper [32], where the incremental
net benefit of control activities in specific geographic locations of
Colombia is determined.
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